Skip to content
value.today

Veracyte, Inc.: valuation

What the market value assumes, and what the company's own statements and its peers' prices would put it at. Every assumption is yours to change.

Cash-flow value and what the price assumes

$M

Average of FY2023–FY2025 (cash from operations less capital spending), from the statements below.

%

Starts at revenue growth over the last three years, 20.4% a year (statements).

%

US Treasury 10-year yield on Nov 20, 2026: 4.92% (US Treasury).

%

Your assumption: the extra yearly return you want for holding shares rather than Treasuries. 5% is a round starting figure, not data.

%

Your assumption: long-run growth, usually near inflation. It must stay below the discount rate.

$M

Debt or cash not on file: 0 to start with.

What today's price assumes

A market value of $3.7 B means free cash flow growing 20.0% a year for 10 years, then 2.5% for ever, at a 9.92% discount rate.

Revenue grew 20.4% a year over the last three years.

Cash-flow value of the shares
$3.8 B
+3% against the market value
Value of the whole business
$3.8 B
before net debt
Value from after year 10
67%
of the business value

Against the market value, for other rates

Cash-flow value of the shares as a percentage above or below today's market value; your inputs in the middle.

Sensitivity of the cash-flow value to the discount rate and the growth rate
Discount rate ↓ / growth →15.37%17.87%20.37%22.87%25.37%
7.92%+4%+25%+52%+83%+120%
8.92%-15%+2%+23%+48%+78%
9.92%-29%-14%+3%+23%+48%
10.92%-39%-27%-12%+5%+25%
11.92%-47%-36%-24%-10%+7%

On one scale

Bars: from the 25th to the 75th percentile multiple of the peers, the line at the median; dot: the cash-flow value with your inputs.

P/EP/E of Biotechnology: $625 M to $3.9 B, median $1.3 BPrice to salesPrice to sales of Biotechnology: $1.2 B to $5.2 B, median $2.6 BPrice to bookPrice to book of Biotechnology: $4.2 B to $17.1 B, median $6.0 BCash-flow value$0 M$4.6 B$9.2 B$13.9 B$18.5 BMarket value $3.7 B

Your own DCF model

A full discounted-cash-flow model of Veracyte, Inc., started from its filings: revenue growth and margins year by year, bear, base and bull cases, the WACC and its parts, sensitivity tables and a value per share against the dated market price. Save it, share it with your team or by a read-only link.

Open the DCF model

Against the industry Biotechnology

Multiples of its companies with a market value at most 60 days old, times Veracyte, Inc.'s own figures of FY2025.

Values from the peers' multiples
MultiplePeers (25th / median / 75th)Veracyte, Inc.Applied toValue (25th to 75th)Companies
P/E9.4× / 19.7× / 59.0×29.4×net income $66 M$625 M to $3.9 B33
Price to sales2.2× / 5.0× / 10.2×6.4×revenue $517 M$1.2 B to $5.2 B84
Price to book3.2× / 4.6× / 13.1×2.9×book equity $1.3 B$4.2 B to $17.1 B69

Against its own history

Veracyte, Inc.'s multiples at each month end with a market cap on file, Jan 2020 to Oct 2026, each against its own median.

P/E

32.6×

Now below its median of 64.9×, in the bottom quarter of its range; range 27.9× to 124.4× over 21 months.

0×31×62×93×124×2026P/E 33×Median 65×

Price to sales

6.6×

Now close to its median of 6.5×; range 4.2× to 23.4× over 30 months.

0×6×12×18×23×2020202120222023202420252026Price to sales 7×Median 6×

Price to book

2.9×

Now above its median of 2.6×; range 1.6× to 16.7× over 30 months.

0×4×8×13×17×2020202120222023202420252026Price to book 3×Median 3×

As of Oct 22, 2026

The statements it starts from

USD millions at each year's exchange rate; free cash flow = cash from operations less capital spending.

Figures from the annual statements
Fiscal yearRevenueNet incomeCash from operationsCapital spendingFree cash flowNet debtSource
FY2025to Dec 31, 2025$517 M$66 M$136 M$10 M$127 M—SEC annual report (10-K, 20-F)
FY2024to Dec 31, 2024$446 M$24 M$75 M$11 M$64 M—SEC annual report (10-K, 20-F)
FY2023to Dec 31, 2023$361 M$-74 M$44 M$10 M$34 M—SEC annual report (10-K, 20-F)
FY2022to Dec 31, 2022$297 M$-37 M$8 M$9 M$-1 M—SEC annual report (10-K, 20-F)
FY2021to Dec 31, 2021$220 M$-76 M$-32 M$5 M$-37 M$-173 MSEC annual report (10-K, 20-F)
FY2020to Dec 31, 2020$117 M$-35 M$-10 M$3 M$-13 M$-349 MSEC annual report (10-K, 20-F)